Alx Oncology Holdings Inc (ALXO) Stock Price & Analysis
Alx Oncology Holdings Inc (ALXO) fell 1.27% to USD 1.55 as of June 10, 2026 at 01:48 UTC, according to Nexqual real-time market data.
ALXO last closed at USD 1.57; the session ranged USD 1.52–1.62 on volume of 501,801 shares. Market capitalization is $208.57M, with a 52-week range of USD 0.4–2.66 (NMS). Source: Nexqual, June 10, 2026 at 01:48 UTC.
Key Statistics (as of June 10, 2026 at 01:48 UTC)
| Price | USD 1.55 |
|---|---|
| Change | ▼ 1.27% (down) |
| Previous Close | USD 1.57 |
| Open | USD 1.58 |
| Day Range | USD 1.52 – 1.62 |
| 52-Week Range | USD 0.4 – 2.66 |
| Volume | 501,801 shares |
| Market Cap | $208.57M |
| Exchange | NMS |
Technical Analysis (ALXO)
Nexqual's technical model rates ALXO "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35 (neutral) |
| vs SMA50 | Below (USD 1.82) |
| MACD | -0.09 (negative) |
Analyst Ratings (ALXO)
Wall Street analysts rate ALXO "Strong Buy" based on 5 analysts, with a mean price target of USD 4.6 (range USD 4–6), per Nexqual as of June 10, 2026 at 01:48 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.6 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (ALXO)
| Next Earnings Date | 2026-05-08 |
|---|---|
| EPS Estimate | USD -0.16 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.16 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.32 ▼ miss |
| 2025-09-30 | USD -0.41 vs est -0.37 ▼ miss |
| 2025-06-30 | USD -0.44 vs est -0.31 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:48 UTC.
Financials & Fundamentals (ALXO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.17% |
| Debt / Equity | 5.62 |
| Current Ratio | 7.21 |
| Total Cash | $140.32M |
| Total Debt | $8.51M |
| Free Cash Flow | $-43.27M |
Source: Nexqual, June 10, 2026 at 01:48 UTC.
Financial Health Score (ALXO)
Nexqual rates Alx Oncology Holdings Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $140M cash vs $9M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$78M |
| Efficiency | Critical — ROE -74%, ROA -36.8% |
Ownership (ALXO)
| Insider Ownership | +0.92% |
|---|---|
| Institutional Ownership | +78.77% |
| Shares Outstanding | 134.56M |
| Float | 107.02M |
| Short % of Float | +1.41% |
Source: Nexqual, June 10, 2026 at 01:48 UTC.
Leadership (ALXO)
Alx Oncology Holdings Inc is led by Jason W. Lettmann (age 48), CEO & Director, per Nexqual as of June 10, 2026 at 01:48 UTC.
| CEO & Director | Jason W. Lettmann (age 48) |
|---|---|
| Chief Financial Officer | Harish Shantharam C.F.A. (age 44) |
| Senior Vice President of Clinical Development | Athanasios Tsiatis |
| Senior Vice President of Drug Safety & Pharmacovigilance | Lin Yeong-Liang M.D., M.S. |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Lisa Sauer |
Major Backers & Investors (ALXO)
Notable institutional backers of Alx Oncology Holdings Inc include RA Capital Management, L.P., TCG Crossover Management, LLC, venBio Partners LLC, according to Nexqual as of June 10, 2026 at 01:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.67% |
| TCG Crossover Management, LLC | 9.67% |
| venBio Partners LLC | 9.58% |
| Redmile Group, LLC | 5.92% |
| Blackstone Inc | 4.33% |
| Driehaus Capital Management, LLC | 4.26% |
| Marshall Wace LLP | 2.79% |
| Vivo Capital, LLC | 2.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.29% |
Source: Nexqual, June 10, 2026 at 01:48 UTC.
From Alx Oncology Holdings Inc's Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
- The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
- It has license agreements with Board of Trustees of Leland Stanford Junior University.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NKTX | Nkarta, Inc. | USD 2.45 | ▼ 2.39% |
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 3.58 | ▼ 2.19% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.05 | ▼ 6.25% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:48 UTC. This page is informational and not investment advice.